KV Pharmaceutical (KV.A) Announces Licensing Agreement with Gedeon Richter
KV Pharmaceutical Company (NYSE: KV.A) (NYSE: KV.B) has entered into an agreement with Gedeon Richter, Plc. of Budapest, Hungary, and jointly with Gedeon Richter USA for licensing rights to certain of KV's technologies and products in Women's Health. The agreement expands the parties' relationship and allows Gedeon Richter rights to manufacture and distribute certain of KV's proprietary technologies and products in its territories, including the European Union. KV Pharmaceutical will receive undisclosed milestones and royalties for products developed under the terms of the agreement.
The agreement also provides for the development of additional products in the future. KV retains the rights to the products and technology in the US.
KV Pharmaceutical Company is a fully integrated specialty pharmaceutical company that develops, manufactures, markets, and acquires technology-distinguished branded and generic/non-branded prescription pharmaceutical products.[SM]
The agreement also provides for the development of additional products in the future. KV retains the rights to the products and technology in the US.
KV Pharmaceutical Company is a fully integrated specialty pharmaceutical company that develops, manufactures, markets, and acquires technology-distinguished branded and generic/non-branded prescription pharmaceutical products.[SM]
You May Also Be Interested In
- K-V Pharmaceutical Company States That Its Policy is Not to Comment on Unusual Market Activity
- CNH Global N.V. (CNH) Stops Doing Business with Iran
- Facebook (FB) Debuts New Camera App, Will Compete with Instagram
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
